Although researchers emphasized more research is necessary, a study in Blood Advances demonstrated that tocilizumab may be an effective treatment for patients with COVID-19 and hematologic malignancies.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
Although researchers emphasized more research is necessary, a study in Blood Advances demonstrated that tocilizumab may be an effective treatment for patients with COVID-19 and hematologic malignancies.